Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo

Extension through Nov. 11, 2023, gives DEA and HHS a chance to consider revisions and public comments regarding proposals offered March 1

Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior

Improvement observed across a range of health conditions, mostly sustained over time

Adults identifying as bisexual or 'something else' have highest prevalence of chronic pain

Overall risk of CUD on schizophrenia was slightly higher among men than women

Overdose prevention centers allow people to use illegal drugs under supervision so they can potentially be revived if they overdose

Both residential and outpatient individuals with schizophrenia tended to have fewer active hours during the day

Those with four or more ACEs by the fall of 2020 had 2.71-fold increased likelihood of reporting a new ACE in spring of 2021

There are both benefits and harms involved in social media use, and the report authors sought a balanced approach